NEW YORK, Jan. 15 - DeCode genetics has launched a pharmacogenomics alliance with Pharmacia in order to probe the genetics of heart disease progression, the company said on Tuesday.
The companies hope to isolate genetic markers that can be used to identify patients who will benefit from the cardiovascular drugs that Pharmacia is currently developing. Specifically, under terms of the deal, deCode will use its population data and genetic marker-discovery techniques to identify patients who are predisposed to progress rapidly from early-stage to advanced heart disease.
Terms of the deal further call for the Icelandic population genetics company will receive contract fees through Encode, its pharmacogenomics, and CRO subsidiary. Encode may also receive royalties on diagnostic tests or cardiovascular drug sales, if Pharmacia exercises license options.
Further financial details were not disclosed.
The therapeutic goal of the partnership is to make it possible early on to identify patients who are likely to develop advanced heart disease, and provide preventive treatment, deCode CEO Kari Stefansson said in a statement.